Filing Flows › Comparisons › INDV vs BBIO
Indivior Pharmaceuticals vs BridgeBio Pharma: INDV and BBIO compared
Indivior Pharmaceuticals is the larger company: $356M of revenue in its latest quarter (Q3 2026) against $353M for BridgeBio Pharma (Q3 2026). BridgeBio Pharma is growing faster (+193% against +13% a year earlier). Indivior Pharmaceuticals is more profitable, with an operating margin of 50.6% against -3.3%.
Where the money goes: INDV and BBIO
Indivior Pharmaceuticals (INDV) · Q3 2026
Indivior Pharmaceuticals, Q3 2026: revenue $356M (+13% year over year), operating margin 50.6%, net earnings $137M, operating cash flow $97.0M. The chart follows the revenue to costs, profit and cash.
BridgeBio Pharma (BBIO) · Q3 2026
BridgeBio Pharma, Q3 2026: revenue $353M (+193% year over year), operating margin -3.3%, net loss $60.5M, operating cash flow −$44.2M. The chart follows the revenue to costs, profit and cash.
| Indivior Pharmaceuticals (INDV) | BridgeBio Pharma (BBIO) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $356M | $353M |
| Revenue growth, Y/Y | +13% | +193% |
| Gross margin | 85.7% | — |
| Operating margin | 50.6% | -3.3% |
| Net earnings | $137M | −$60.5M |
| Net margin | 38.5% | -17.1% |
| Operating cash flow | $97.0M | −$44.2M |
| Free cash flow | $83.0M | — |
| Market value | $4.4B | $14.6B |
| P/E | 10.1× | — |
| Analysts’ mean target | $49.50 | $106.85 |
Where the revenue comes from
BridgeBio Pharma
- Net product revenue: $253M (72%)
- License and services revenue: $79.3M (22%)
- Royalty revenue: $20.5M (6%)
Questions
Which is bigger, Indivior Pharmaceuticals or BridgeBio Pharma?
Indivior Pharmaceuticals is the larger company: $356M of revenue in its latest quarter (Q3 2026) against $353M for BridgeBio Pharma (Q3 2026).
Is Indivior Pharmaceuticals or BridgeBio Pharma growing faster?
BridgeBio Pharma is growing faster (+193% against +13% a year earlier).
Which is more profitable, Indivior Pharmaceuticals or BridgeBio Pharma?
Indivior Pharmaceuticals is more profitable, with an operating margin of 50.6% against -3.3%.
More: Indivior Pharmaceuticals earnings · how Indivior Pharmaceuticals makes money · BridgeBio Pharma earnings · how BridgeBio Pharma makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Oct 29, 2026; 10-Q filed Oct 29, 2026). Fiscal quarters can end on different dates. Not investment advice.